The acquisition strengthens Bausch + Lomb’s clinical-stage pipeline. Whitecap’s therapies are focused on glaucoma and geographic atrophy. Bausch + Lomb acquired Whitecap Biosciences ...
It provides range of vision beyond one focal point. Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release. Using intermediate ...
In the US, enVista Aspire is the first Low-Cyl toric IOL below 1.5D at the IOL plane, enhancing treatment options. Bausch + Lomb announced the commercial launch of its enVista Aspire monofocal and ...
VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an ...
VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the ...
Bausch + Lomb acquired Whitecap Biosciences to develop therapies for glaucoma and geographic atrophy, aiming to improve visual outcomes. Whitecap's WB007, an alpha-2 adrenergic agonist, showed IOP ...
City Therapeutics, Inc. set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback